Boehringer offers its molecules to the scientific community via new platform
pharmafile | November 21, 2017 | News story | Manufacturing and Production, Research and Development | Boehringer Ingelheim, pharma
Boehringer Ingelheim has unveiled opnME.com, a centralised platform which makes available selected pre-clinical molecules from its portfolio for free, accessible for non-clinical investigation by scientists worldwide.
The German drugmaker hopes that the move will galvanise independent drug discovery and collaborative partnerships, as well as the identification of novel treatment solutions for patients.
The available molecules are divided into two distinct groups. For the most part, molecules are offered via a simple shopping cart system and do not require any specific intellectual property discussion. For the remaining molecules, a crowdsourcing option is available which is designed to facilitate collaboration. These molecules require a research proposal to be submitted, and if it is successful, the chosen candidate will work together with Boehringer scientists on research and development on the project.
“Working together with scientists across the world, we can accelerate research in a wide range of biomedical research areas,” explained Dr Clive R Wood, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “This exciting new initiative further expands Boehringer Ingelheim’s global external innovation footprint and will help unlock the full potential of some of our most interesting compounds. By sharing these compounds with scientists around the world, we will advance scientific research and expect to spark discoveries that will lead to safe and effective new medicines for patients.”
opnME.com represents another of Boehringers initiatives to drive research and collaboration in the industry, joining the likes of the company’s Research Beyond Borders and the Boehringer Ingelheim Venture Fund initiatives.
Wood added: “I invite interested scientists worldwide to visit opnMe.com to access our molecules. We will measure the success of this initiative in terms of new experiments, publications and relationships forged. This approach to open innovation reflects our determination to break down barriers to the advancement of biomedical research and bring breakthrough medicines to patients”
Matt Fellows
Related Content
Boehringer Ingelheim’s Spevigo gains additional approvals in US and China
Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and …
Boehringer Ingelheim announces results from phase 2 trial for liver disease treatment
Boehringer Ingelheim has announced results from the phase 2 trial of survodutide for the treatment …
FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment
Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) …
